Lead DMPK strategy for small-molecule drug discovery through IND, integrating ADME, PK/PD, and translational modeling. Guide cross-functional teams, manage external vendors, predict human PK/dose, assess drug interaction risk, and author nonclinical pharmacology sections for regulatory filings.
Director/Senior Director, DMPK
Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function. The company’s most advanced programs target NLRP3 and SARM1, with additional programs in preclinical development.
We are looking for a highly motivated and skilled DMPK Scientist with scientific leadership experience in small molecule drug discovery and early development. Reporting to the Vice President, DMPK & Clinical Pharmacology, this role will direct the translational ADME and PK/PD strategies for drug discovery and early development of small molecule therapeutics. This leader will drive pipeline progression from lead identification and optimization through IND with key deliverables of human PK and efficacious dose predictions and clinical risk assessment based on translating in vitro and nonclinical data. This is an excellent opportunity to join a biotech company with groundbreaking work in the field. This role is onsite.
JOB RESPONSIBILITIES:
- Be a subject matter expert in DMPK who applies a robust and scientifically rigorous DMPK strategy across the pipeline of small molecule drug discovery to early development
- Guide interdisciplinary project teams to integrate DMPK strategies of ADME and PK/PD principles early in discovery
- Partner with chemistry, biology, pharmacology, toxicology, biomarker, and clinical to drive progression of lead molecules to IND- and clinical-readiness
- Manage and oversee external vendors for completing in vitro and in vivo ADME, PK and TK studies
- Utilize PK and PK/PD modeling for human dose and PK predictions and drug interaction risk assessments
- Serve as a subject matter expert to author and review Nonclinical Pharmacology sections of regulatory (IND/CTA) filings, IB updates, and responses to regulatory queries
QUALIFICATIONS:
- MS or PhD in Drug Metabolism, Pharmacokinetics, Chemistry, or related scientific discipline with a minimum 8+ years of pharmaceutical drug discovery and development experience
- Strong track record of supporting drug discovery and development through executing and updating ADME, PK, and translational strategy
- Excellent critical thinking and scientific skills with proven scientific expertise in small molecule metabolism and pharmacokinetics
- Demonstrated success working effectively and collaboratively on cross-functional projects teams
- $240,000-290,000 annual base salary
Tenvie is proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability or any other status protected under federal, state or local law. All employment is decided on the basis of qualifications, merit and business need.
Tenvie Therapeutics South San Francisco, California, USA Office
161 Oyster Point Blvd, South San Francisco, California, United States, 94080
Similar Jobs
Biotech • Pharmaceutical
Lead and grow the DMPK function to support discovery through IND/NDA enabling studies. Provide scientific strategy for ADME/PK/PD, advise cross-functional teams on lead optimization, design and report preclinical studies, address drug-drug interaction risks, and support regulatory submissions. Recruit and mentor staff, implement innovative methods, and represent DMPK on program teams.
Top Skills:
AdmeDmpkDrug-Drug Interaction AssessmentIn Vitro AssaysIn Vivo PkInd/Nda Regulatory SubmissionsPk/Pd
Artificial Intelligence • Software • Biotech
Lead the DMPK function by defining scientific strategies, collaborating with teams to execute studies, and ensuring regulatory compliance while managing research initiatives and partnerships.
Top Skills:
AdmeDmpkFda RegulationsIch GuidelinesPd ModelingPkRegulatory Guidelines
Biotech
The Senior DMPK Director leads DMPK strategies for drug candidates, oversees studies, prepares regulatory documents, and collaborates across departments to inform drug development decisions.
Top Skills:
AdmeBlaDrug MetabolismIndModelingNdaPharmaceutical SciencesPharmacokineticsSimulations
What you need to know about the San Francisco Tech Scene
San Francisco and the surrounding Bay Area attracts more startup funding than any other region in the world. Home to Stanford University and UC Berkeley, leading VC firms and several of the world’s most valuable companies, the Bay Area is the place to go for anyone looking to make it big in the tech industry. That said, San Francisco has a lot to offer beyond technology thanks to a thriving art and music scene, excellent food and a short drive to several of the country’s most beautiful recreational areas.
Key Facts About San Francisco Tech
- Number of Tech Workers: 365,500; 13.9% of overall workforce (2024 CompTIA survey)
- Major Tech Employers: Google, Apple, Salesforce, Meta
- Key Industries: Artificial intelligence, cloud computing, fintech, consumer technology, software
- Funding Landscape: $50.5 billion in venture capital funding in 2024 (Pitchbook)
- Notable Investors: Sequoia Capital, Andreessen Horowitz, Bessemer Venture Partners, Greylock Partners, Khosla Ventures, Kleiner Perkins
- Research Centers and Universities: Stanford University; University of California, Berkeley; University of San Francisco; Santa Clara University; Ames Research Center; Center for AI Safety; California Institute for Regenerative Medicine
